FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313478997> ?p ?o ?g. }

• W4313478997 endingPage "139" @default.
• W4313478997 startingPage "132" @default.
• W4313478997 abstract "Thymic carcinoma (TC) is a rare cancer and patients failing initial chemotherapy (relapse/refractory) face limited therapeutic options given no approved options or consensus standard of care. This study aimed to identify and summarize clinical outcomes of all regimens evaluated in clinical trials of relapsed or refractory patients. Interventional trials enrolling advanced TC patients who failed first-line chemotherapy and reported outcomes in this group were eligible for inclusion in our systemic literature review (SLR). Between-study heterogeneity was assessed to determine the feasibility of pooling specific studies and treatments. Objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and duration of response (DOR) endpoints were of interest for meta-analysis. Nineteen trials were identified in the SLR. Three trials with one or two TC patients were removed from our assessment to reduce publication bias. Response rates among studies with at least ten TC patients varied from 9 % to 38 %. Pooled ORRs in patients receiving S-1 (46 patients), sunitinib (46 patients), or pembrolizumab (66 patients) were 28 %, 24 %, and 21 %, respectively. Prolonged duration of response with pembrolizumab was observed with a pooled median of 23.8 months (95 % confidence interval [CI]: 12, not reached). Median PFS of five months or greater was reported in patients treated with sunitinib, lenvatinib, pembrolizumab, capecitabine + gemcitabine, everolimus, or S-1. Median OS of 20 months or greater was reported in trials evaluating S-1 or pembrolizumab; this endpoint was not reached in trials evaluating lenvatinib, regorafenib, or sunitinib. Generalizability of treatment effects is challenging in the research of rare diseases and meta-analysis of clinical outcomes may help to increase precision and relevance of results to the larger TC population. Our study found limited treatment options upon relapse, demonstrating a need for further investigations into novel therapeutics and well-powered clinical trials to better inform on optimal treatments." @default.
• W4313478997 created "2023-01-06" @default.
• W4313478997 creator A5039522622 @default.
• W4313478997 creator A5061816287 @default.
• W4313478997 creator A5068743826 @default.
• W4313478997 creator A5083748366 @default.
• W4313478997 creator A5089742497 @default.
• W4313478997 date "2023-02-01" @default.
• W4313478997 modified "2023-09-26" @default.
• W4313478997 title "Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis" @default.
• W4313478997 cites W1767875808 @default.
• W4313478997 cites W1978029935 @default.
• W4313478997 cites W1980743422 @default.
• W4313478997 cites W1982967337 @default.
• W4313478997 cites W1989429100 @default.
• W4313478997 cites W1991142118 @default.
• W4313478997 cites W2012510274 @default.
• W4313478997 cites W2014718521 @default.
• W4313478997 cites W2025363005 @default.
• W4313478997 cites W2032955956 @default.
• W4313478997 cites W2040251898 @default.
• W4313478997 cites W2042388452 @default.
• W4313478997 cites W2057765075 @default.
• W4313478997 cites W2059573268 @default.
• W4313478997 cites W2064726511 @default.
• W4313478997 cites W2074182195 @default.
• W4313478997 cites W2080181833 @default.
• W4313478997 cites W2083996649 @default.
• W4313478997 cites W2086023535 @default.
• W4313478997 cites W2093609355 @default.
• W4313478997 cites W2094874636 @default.
• W4313478997 cites W2124847703 @default.
• W4313478997 cites W2128986224 @default.
• W4313478997 cites W2130099089 @default.
• W4313478997 cites W2137591261 @default.
• W4313478997 cites W2151067943 @default.
• W4313478997 cites W2151632124 @default.
• W4313478997 cites W2159529352 @default.
• W4313478997 cites W2167601464 @default.
• W4313478997 cites W2168558240 @default.
• W4313478997 cites W2225401099 @default.
• W4313478997 cites W2232731174 @default.
• W4313478997 cites W2333507027 @default.
• W4313478997 cites W2468996569 @default.
• W4313478997 cites W2594098019 @default.
• W4313478997 cites W2613990243 @default.
• W4313478997 cites W2742400616 @default.
• W4313478997 cites W2784751095 @default.
• W4313478997 cites W2789283644 @default.
• W4313478997 cites W2808003286 @default.
• W4313478997 cites W2885496181 @default.
• W4313478997 cites W2890103368 @default.
• W4313478997 cites W2891885060 @default.
• W4313478997 cites W2896211882 @default.
• W4313478997 cites W2898105641 @default.
• W4313478997 cites W2901757914 @default.
• W4313478997 cites W2938876444 @default.
• W4313478997 cites W2975424845 @default.
• W4313478997 cites W2978457838 @default.
• W4313478997 cites W2980505640 @default.
• W4313478997 cites W2981337061 @default.
• W4313478997 cites W2997341660 @default.
• W4313478997 cites W3004108187 @default.
• W4313478997 cites W3011919019 @default.
• W4313478997 cites W3034160707 @default.
• W4313478997 cites W3050824642 @default.
• W4313478997 cites W3057650047 @default.
• W4313478997 cites W3109934647 @default.
• W4313478997 doi "https://doi.org/10.1016/j.lungcan.2023.01.003" @default.
• W4313478997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36638588" @default.
• W4313478997 hasPublicationYear "2023" @default.
• W4313478997 type Work @default.
• W4313478997 citedByCount "1" @default.
• W4313478997 countsByYear W43134789972023 @default.
• W4313478997 crossrefType "journal-article" @default.
• W4313478997 hasAuthorship W4313478997A5039522622 @default.
• W4313478997 hasAuthorship W4313478997A5061816287 @default.
• W4313478997 hasAuthorship W4313478997A5068743826 @default.
• W4313478997 hasAuthorship W4313478997A5083748366 @default.
• W4313478997 hasAuthorship W4313478997A5089742497 @default.
• W4313478997 hasBestOaLocation W43134789971 @default.
• W4313478997 hasConcept C121608353 @default.
• W4313478997 hasConcept C126322002 @default.
• W4313478997 hasConcept C141071460 @default.
• W4313478997 hasConcept C143998085 @default.
• W4313478997 hasConcept C2776248978 @default.
• W4313478997 hasConcept C2776264508 @default.
• W4313478997 hasConcept C2777701055 @default.
• W4313478997 hasConcept C2779490328 @default.
• W4313478997 hasConcept C2779699572 @default.
• W4313478997 hasConcept C2779761222 @default.
• W4313478997 hasConcept C2780057760 @default.
• W4313478997 hasConcept C526805850 @default.
• W4313478997 hasConcept C535046627 @default.
• W4313478997 hasConcept C71924100 @default.
• W4313478997 hasConceptScore W4313478997C121608353 @default.
• W4313478997 hasConceptScore W4313478997C126322002 @default.
• W4313478997 hasConceptScore W4313478997C141071460 @default.

• next